9 Ways Perimenopause Symptoms Differ by Ethnicity and Why That Matters for Treatment
One of the things that bothered me most when researching this site was how often 'standard' menopause advice turned out to mean 'advice based on white women in clinical trials.' If you've ever felt like the information didn't quite match your experience, there's a real scientific reason for that — and you deserved better information years ago.
Learn more about Rose →Black Women Report the Most Frequent and Severe Hot Flashes
SWAN data consistently shows that Black women experience hot flashes more frequently, rate them as more bothersome, and endure them for longer durations than women of other ethnic groups — with some analyses showing hot flash prevalence nearly 50% higher than in white women. The biological mechanisms aren't fully understood, but differences in cardiovascular reactivity, stress hormone patterns, and socioeconomic stressors that affect thermoregulatory thresholds are all being investigated. This matters clinically because it means Black women may need earlier intervention conversations, yet research also shows they are less likely to be offered or prescribed hormone therapy.
Japanese and Chinese Women Report Fewer Hot Flashes — But More Joint Pain
In SWAN, Japanese and Chinese American women consistently reported the lowest rates of hot flashes of any group studied, a finding that has prompted research into dietary factors (including soy isoflavone intake), genetic differences in estrogen metabolism, and cultural variation in symptom reporting. However, the same women reported higher rates of joint pain and stiffness, a symptom that often goes unrecognised as hormone-related. This pattern suggests that clinicians treating Asian women in perimenopause should ask specifically about musculoskeletal symptoms rather than leading with vasomotor ones.
Hispanic Women Experience a Distinct Symptom Profile Weighted Toward Mood
SWAN and related studies found that Hispanic women reported higher rates of depressive symptoms during the menopausal transition compared to white women, even after controlling for socioeconomic and lifestyle factors. They also reported more sleep disturbances and a higher symptom burden overall, including urinary complaints. Because depression and sleep disruption can be attributed to life circumstances rather than hormonal change, there is a real risk of under-treatment if clinicians don't recognise these as part of a perimenopausal pattern.
Bone Loss Trajectories Are Not Equal Across Ethnic Groups
Black women tend to enter perimenopause with higher baseline bone mineral density than white, Asian, or Hispanic women, which partially explains lower lifetime fracture rates — but this can lead to a dangerous clinical assumption that Black women don't need bone health monitoring. Asian women, particularly those of East Asian descent, have lower baseline bone density and accelerated loss around the final menstrual period, placing them at meaningful fracture risk. The evidence is clear that fracture risk screening thresholds built on white-population averages will miss at-risk women in other groups.
Age at Final Menstrual Period Varies Meaningfully by Ethnicity
SWAN data shows that Hispanic and Black women tend to reach natural menopause slightly earlier than white women, while Japanese women tend to reach it slightly later — differences of one to two years on average. Earlier menopause translates to a longer post-menopausal window of estrogen deficiency, which compounds cardiovascular and bone risks over a lifetime. A woman who reaches menopause at 49 instead of 52 has three additional years of exposure to those risks, making the timing itself clinically relevant.
Depression Risk During the Transition Is Not Uniform
Research drawing on SWAN and the Penn Ovarian Aging Study shows that while all women face elevated depression risk during perimenopause due to fluctuating estradiol, the magnitude of that risk differs by ethnicity. Black and Hispanic women show higher rates of clinically significant depressive symptoms during the transition, a disparity that persists after adjusting for income, education, and stress. Some researchers hypothesise that chronic allostatic load — the cumulative biological toll of systemic stressors — sensitises the HPA axis in ways that interact with estrogen withdrawal, though this remains an active area of research.
Sleep Architecture Disruption Hits Some Groups Earlier and Harder
SWAN's sleep sub-study found that Black women reported more trouble sleeping and more night waking than white women at equivalent hormonal stages, independent of hot flash frequency — suggesting the sleep disruption isn't solely driven by vasomotor symptoms. This is an important distinction because it means treating hot flashes alone may not resolve sleep problems for Black women, and a more comprehensive approach to sleep is warranted. Clinicians and women themselves benefit from knowing that poor sleep during perimenopause isn't simply a downstream effect of sweating through the night.
Cardiovascular Risk Windows Differ — and Are Often Missed
The decline in estrogen during perimenopause triggers changes in lipid profiles, blood pressure, and vascular stiffness, but the rate and magnitude of these changes vary by ethnicity. Black women show more rapid increases in blood pressure during the menopausal transition compared to white women, a pattern linked to higher lifetime cardiovascular mortality. These differences mean that standard cardiovascular screening intervals designed around average populations may leave some women unmonitored during their highest-risk window.
Access to — and Uptake of — HRT Reflects Systemic Inequity, Not Just Preference
Studies consistently show that Black and Hispanic women are less likely to be offered hormone therapy and less likely to receive it even when symptomatic, a disparity that cannot be explained by symptom severity alone since Black women report among the highest symptom burdens. Distrust of the medical system rooted in historical mistreatment, language barriers, provider bias, and insurance access all contribute to treatment gaps that have real consequences for quality of life and long-term health. Closing this gap requires clinicians to actively offer evidence-based treatment conversations rather than waiting for patients to raise the subject.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.